View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Sid Rajeev
  • Sid Rajeev

Delivra Health (DHB) FY2025 Beat: Expansion & M&A Drive Growth - Repor...

Delivra Health Brands Inc. (TSXV: DHB / OTCQB: DHBUF) reported FY2025 (ended June 30, 2025) revenue growth of 8% YoY, surpassing estimates by 3%, fueled by robust Dream Water sales in the U.S. and Middle East. The company's share price has surged 93% YTD, outperforming the S&P Personal Care Index, which declined 7%. Marketing expenses increased 26% YoY to 15% of revenue, aligning with guidance to boost growth. Adjusted EPS was ($0.02), a 12% drop but beating the estimated ($0.04) due to higher r...

Dan Salmon
  • Dan Salmon

Amazon (Buy, $270 target) Price increase rejuvenates the AWS bull cas...

AWS has raised publicly-listed Capacity Block pricing on B200 instances, a material and unexpected positive development supporting our above-consensus revenue estimates for AWS.

Dan Salmon
  • Dan Salmon

AWS/GCP: How long does it take to pay off an XPU?

We take a closer look at how long it takes for AWS and GCP to pay back the investment in both GPUs and custom chips (TPUs and Trainium) on both a revenue and contribution margin basis, using our estimates of per-chip costs and realized pricing for each of AWS and GCP.

Dan Salmon
  • Dan Salmon

GOOGL/AMZN/META: Updated AI D&A and Lower META AI RO

we've updated our bottom-up AI depreciation analysis for GOOGL, AMZN and META following our latest AI capex update (see HERE).

Amazon Com Inc: 1 director

A director at Amazon Com Inc sold 2,500 shares at 217.100USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
LAC. LITHIUM AMERICAS CORP NEW
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Dan Salmon
  • Dan Salmon

Updated AI ROICs: AMZN higher, GOOGL lower, META mixed

Our updated AI ROIC estimates reflect the latest AI Capex and Cloud AI revenue updates. The original AI ROIC analysis is HERE. In the report, we review changes for each company and the primary drivers of AI returns.

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt
Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Counting Clicks: August '25 Traffic Trends

Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr

Walmart Inc: 1 director

A director at Walmart Inc sold 19,416 shares at 103.213USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Dan Salmon
  • Dan Salmon

GOOGL/AMZN: 2Q25 AI Revenues – Remain Above Street for AWS/GCP

We have updated our bottom-up estimates for Amazon Web Services (AWS) and Google Cloud Platform’s (GCP) revenues from AI products and services. We remain above consensus for 2H25 and 1H26 for both GCP and AWS total revenue growth.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch